Daré Bioscience (NASDAQ:DARE) Share Price Passes Above 50-Day Moving Average – Should You Sell?

Daré Bioscience, Inc. (NASDAQ:DARE) shares passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $3.19 and traded as high as $3.23. Daré Bioscience shares last traded at $3.13, with a volume of 49,857 shares traded.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Daré Bioscience in a research report on Tuesday, December 17th.

Daré Bioscience Stock Performance

The stock’s fifty day simple moving average is $3.19 and its two-hundred day simple moving average is $3.38. The stock has a market capitalization of $27.23 million, a P/E ratio of -5.30 and a beta of 1.32.

Institutional Trading of Daré Bioscience

A number of institutional investors and hedge funds have recently bought and sold shares of DARE. Geode Capital Management LLC lifted its holdings in Daré Bioscience by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock worth $289,000 after buying an additional 3,593 shares during the period. Renaissance Technologies LLC increased its stake in shares of Daré Bioscience by 6.7% in the fourth quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock valued at $214,000 after buying an additional 4,300 shares during the period. Jane Street Group LLC bought a new position in shares of Daré Bioscience during the fourth quarter worth about $52,000. Finally, AMH Equity Ltd raised its position in shares of Daré Bioscience by 50.0% during the fourth quarter. AMH Equity Ltd now owns 150,000 shares of the biotechnology company’s stock worth $468,000 after acquiring an additional 50,000 shares during the last quarter. 6.70% of the stock is currently owned by institutional investors and hedge funds.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.